West Pharmaceutical Services has resumed operations following a cybersecurity attack and reported a strong Q1 2026 revenue of $844.9 million, a 21% increase year-over-year. The company raised its 2026 earnings forecasts and expects no material financial impact from the incident, leading analysts to raise their price targets significantly. However, investors facing substantial losses have been urged to seek legal counsel ahead of a July 7 deadline for a class action lawsuit.
“West Pharmaceutical Services · restored operations · its sites · after a cybersecurity attack”
“West Pharmaceutical Services · expects · no material impact · on its 2026 financial outlook”
“West Pharmaceutical Services (WST) · reported a · strong Q1 2026 revenue · $844.9 million”
“West Pharmaceutical Services (WST) · achieved a · year-over-year increase in revenue · 21%”
“West Pharmaceutical Services (WST) · experienced a · stock increase · 12.4%”
“West Pharmaceutical Services, Inc. · was founded by · Herman O. West · July 27, 1923”
“West Pharmaceutical Services, Inc. · is headquartered in · Exton, PA”
“WST · is trading near · the top of its 52-week range”
“West Pharmaceutical Services · reports · Q1 adjusted EPS · $2.13, consensus $1.68”
“West Pharmaceutical Services · raises · 2026 outlook · After Strong Quarter”
“West Pharmaceutical Services · sees · Q2 adjusted EPS · $2.05-$2.12, consensus $2.00”
“West Pharmaceutical Services · ups · FY26 adjusted EPS view · $8.40-$8.75 from $7.85-$8.20”